Rola aktywacji receptorów dla insulinopodobnych czynników wzrostu w raku jelita grubego Review article
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
lip 20, 2017
Słowa kluczowe:
rak jelita grubego, insulinopodobne czynniki wzrostu, receptory IGF, zaburzenia metaboliczne
##plugins.themes.bootstrap3.article.main##
Abstrakt
Współwystępowanie zaburzeń metabolicznych jest uznanym czynnikiem ryzyka rozwoju raka jelita grubego, który obecnie zajmuje czołowe miejsce wśród przyczyn chorobowości z powodu nowotworów złośliwych na świecie. Patogeneza rozwoju raka jelita nadal jednak nie została dobrze poznana. Wśród postulowanych mechanizmów nowotworzenia wymienia się aktywację systemu insulinopodobnych czynników wzrostu. O ich roli donoszą zarówno obserwacje epidemiologiczne, jak i kliniczne. W prezentowanym artykule autorzy dokonują syntezy dotychczasowej wiedzy na temat znaczenia aktywacji szlaku insulinopodobnych czynników wzrostu w rozwoju raka jelita grubego.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.generic.paperbuzz.metrics##
##plugins.generic.paperbuzz.loading##
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Walkiewicz K, Nowakowska-Zajdel E, Strzelczyk J, Walczak M, Copija A, Janion K, Muc-Wierzgoń M. Rola aktywacji receptorów dla insulinopodobnych czynników wzrostu w raku jelita grubego. OncoReview [Internet]. 20 lipiec 2017 [cytowane 4 grudzień 2024];7(3(27):116-20. Dostępne na: https://journalsmededu.pl/index.php/OncoReview/article/view/463
Numer
Dział
ENDOCRINOLOGY IN ONCOLOGY
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Krajowy Rejestr Nowotworów (KRN, National Cancer Registry). Online: http://onkologia.org.pl/ (access: December 2016).
2. Baena R, Salinas P. Diet and colorectal cancer. Maturitas. European Menopause Journal 2015; 80(3): 258-264.
3. Rohdenburg GL, Bernhard A, Krehbiel O. Sugar tolerance in cancer. J Am Med Assoc 1919; 72: 1528-1530.
4. Czyżyk A, Szczepanik Z. Diabetes mellitus and cancer. Eur J Intern Med 2000; 11: 245-252.
5. Giovanucci E. Insulin and colon cancer. Cancer Causes & Control 1995; 6(2): 164-179.
6. Gallagher EJ, LeRoith D. Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care 2013; 36 (suppl 2): 233-239.
7. Godsland IF. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci 2010; 118: 315-332.
8. Muc-Wierzgoń M, Nowakowska-Zajdel E, Dzięgielewska-Gęsiak S et al. Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer. World J Gastroenterol 2014; 20(29): 9759-9774.
9. Hopkins BD, Goncalves MD, Cantley LC. Obesity and cancer mechanisms: cancer metabolism. J Clin Oncol 2016; 34(35): 4277-4283.
10. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist 2010; 15: 556-565.
11. Campbell PT, Newton CC, Patel AV et al. Diabetes and cause-specific mortality in a prospective cohort of one million US adults. Diabetes Care 2012; 35: 1835-1844.
12. Wang L, Ma W, Markovich R et al. Insulin-like growth factor I modulates induction of apoptotic signalling in H9C2 cardiac muscle cells. Endocrinology 1998; 139: 1354-1360.
13. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 1999; 20(6): 761-787.
14. Rajah R, Katz L, Nunn S et al. Insulin-like growth factor binding protein (IGFBP) proteases: functional regulators of cell growth. Prog Growth Factor Res 1995; 6(2-4): 273-284.
15. Kreitschmann-Andermahr I, Suarez P, Jennings R et al. GH/IGF-1 regulation in obesity-mechanisms and practical consequences in children and adults. Horm Res Paediatr 2010; 73: 153-160.
16. Juul A. Serum levels of insulin-like growth factor-I and its binding proteins in health and disease. Growth Horm IGF Res 2003; 13: 113-170.
17. LeRoith D. Insulin-like growth factor I receptor signalling – overlapping or redundant pathways? Endocrinology 2000; 141: 1287-1288.
18. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34.
19. Suwała A, Ziora K, Landowska D. Budowa i funkcja insulinopodobnych czynników wzrostowych oraz objawy kliniczne niedoboru IGF-1. Endokrynol Ped 2010; 3: 47-62.
20. Filus A, Zdrojewicz Z. Insulinopodobny czynnik wzrostu-1 (IGF-1) – budowa i rola w organizmie człowieka. Pediatr Endocrinol Diabetes Metab 2014; 22(4): 161-169.
21. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007; 13(7): 671-686.
22. Baxter RC. IGFBP Special Issue. J Cell Commun Signal 2015; 9(2): https://doi.org/101007/s12079-015-0295-5.
23. Józefiak A, Pacholska J, Kędzia W. Rola IGF-1 i IGFBP w procesie neogenezy. Perinatologia, Neonatologia i Ginekologia 2008; 1: 175-183.
24. Bardou M, Barkun AN, Martel M. Obesity and colorectal cancer. Gut 2013; 62: 933-947.
25. Cohen DH, LeRoith D. Obesity, type 2 diabetes and cancer: the insulin and IGF connection. Endocr Relat Cancer 2012; 19: 27-45.
26. Suh S, Kim KW. Diabetes and cancer: is diabetes casually related to cancer? Diabetes Metab J 2011; 35: 193-198.
27. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of insulin-IGF axis. Trends Endocrinol Metab 2006; 17(8): 328-336.
28. Walkiewicz K, Gętek M, Muc-Wierzgoń M et al. The importance of ADAM family proteins in malignant tumours. Post Hig Med Dośw 2016; 70: 67-73.
29. Tinahones FJ, Coin-Araguez L, Mayas MD et al. Obesity-associated insulin resistance is correlated to adipose tissue vascular endothelial growth factors and metalloproteinase levels. BMC Physiology 2012; 12(4): https://doi.org/101186/1472-6793-12-4.
30. Sax AT, Jenkins DG, Devin JL et al. The insulin-like growth factor axis: a biological mechanism linking physical activity to colorectal cancer survival. Cancer Epidemiol 2014; 38: 455-459.
31. Parrizas M, LeRoith D. Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology 1997; 138: 1355-1358.
32. Singh P, Alex JM, Bast F. Insulin receptor, and insulin-like growth factor receptor signalling systems novel treatment strategies of cancer. Med Oncol 2014; 31(805): https://doi.org/101007/s12032-013-0805-3.
33. Nowakowska-Zajdel E, Mazurek U, Wierzgoń J et al. Expression of ADAM 28 and IGFBP-3 genes in patients with colorectal cancer – a preliminary report. Int J Immunopathol Pharmacol 2013; 26: 223-228.
34. Liu JJ, Druta M, Shibata D et al. Metabolic syndrome and colorectal cancer: is hyperinsulineamia/insulin receptor-mediated angiogenesis a critical process? J Geriatr Oncol 2014; 5: 40-48.
35. Hakam A, Yeatman TJ, Lu L et al. Expression of insulin-like growth factor receptor in human colorectal cancer. Hum Pathol 1999; 30(10): 1128-1133.
36. Sandhu MS, Dunger DB, Giovanucci EL. Insulin, insulin-like growth factor-1, IGF bindings proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002; 94(13): 972-980.
37. Durai R, Yang W, Gupta S et al. The role of insulin-like growth factor system in colorectal cancer: a review of current knowledge. Int J Colorectal Dis 2005; 20: 203-220.
38. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16: 143-163.
39. Furlanetto RW, Harwell SE, Frick KK. Insulin-like growth factor-I induces cyclin-D1 expression in MG63 human osteosarcoma cells in vitro. Mol Endocrinol 1994; 8: 510-517.
2. Baena R, Salinas P. Diet and colorectal cancer. Maturitas. European Menopause Journal 2015; 80(3): 258-264.
3. Rohdenburg GL, Bernhard A, Krehbiel O. Sugar tolerance in cancer. J Am Med Assoc 1919; 72: 1528-1530.
4. Czyżyk A, Szczepanik Z. Diabetes mellitus and cancer. Eur J Intern Med 2000; 11: 245-252.
5. Giovanucci E. Insulin and colon cancer. Cancer Causes & Control 1995; 6(2): 164-179.
6. Gallagher EJ, LeRoith D. Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care 2013; 36 (suppl 2): 233-239.
7. Godsland IF. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci 2010; 118: 315-332.
8. Muc-Wierzgoń M, Nowakowska-Zajdel E, Dzięgielewska-Gęsiak S et al. Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer. World J Gastroenterol 2014; 20(29): 9759-9774.
9. Hopkins BD, Goncalves MD, Cantley LC. Obesity and cancer mechanisms: cancer metabolism. J Clin Oncol 2016; 34(35): 4277-4283.
10. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist 2010; 15: 556-565.
11. Campbell PT, Newton CC, Patel AV et al. Diabetes and cause-specific mortality in a prospective cohort of one million US adults. Diabetes Care 2012; 35: 1835-1844.
12. Wang L, Ma W, Markovich R et al. Insulin-like growth factor I modulates induction of apoptotic signalling in H9C2 cardiac muscle cells. Endocrinology 1998; 139: 1354-1360.
13. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 1999; 20(6): 761-787.
14. Rajah R, Katz L, Nunn S et al. Insulin-like growth factor binding protein (IGFBP) proteases: functional regulators of cell growth. Prog Growth Factor Res 1995; 6(2-4): 273-284.
15. Kreitschmann-Andermahr I, Suarez P, Jennings R et al. GH/IGF-1 regulation in obesity-mechanisms and practical consequences in children and adults. Horm Res Paediatr 2010; 73: 153-160.
16. Juul A. Serum levels of insulin-like growth factor-I and its binding proteins in health and disease. Growth Horm IGF Res 2003; 13: 113-170.
17. LeRoith D. Insulin-like growth factor I receptor signalling – overlapping or redundant pathways? Endocrinology 2000; 141: 1287-1288.
18. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34.
19. Suwała A, Ziora K, Landowska D. Budowa i funkcja insulinopodobnych czynników wzrostowych oraz objawy kliniczne niedoboru IGF-1. Endokrynol Ped 2010; 3: 47-62.
20. Filus A, Zdrojewicz Z. Insulinopodobny czynnik wzrostu-1 (IGF-1) – budowa i rola w organizmie człowieka. Pediatr Endocrinol Diabetes Metab 2014; 22(4): 161-169.
21. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007; 13(7): 671-686.
22. Baxter RC. IGFBP Special Issue. J Cell Commun Signal 2015; 9(2): https://doi.org/101007/s12079-015-0295-5.
23. Józefiak A, Pacholska J, Kędzia W. Rola IGF-1 i IGFBP w procesie neogenezy. Perinatologia, Neonatologia i Ginekologia 2008; 1: 175-183.
24. Bardou M, Barkun AN, Martel M. Obesity and colorectal cancer. Gut 2013; 62: 933-947.
25. Cohen DH, LeRoith D. Obesity, type 2 diabetes and cancer: the insulin and IGF connection. Endocr Relat Cancer 2012; 19: 27-45.
26. Suh S, Kim KW. Diabetes and cancer: is diabetes casually related to cancer? Diabetes Metab J 2011; 35: 193-198.
27. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of insulin-IGF axis. Trends Endocrinol Metab 2006; 17(8): 328-336.
28. Walkiewicz K, Gętek M, Muc-Wierzgoń M et al. The importance of ADAM family proteins in malignant tumours. Post Hig Med Dośw 2016; 70: 67-73.
29. Tinahones FJ, Coin-Araguez L, Mayas MD et al. Obesity-associated insulin resistance is correlated to adipose tissue vascular endothelial growth factors and metalloproteinase levels. BMC Physiology 2012; 12(4): https://doi.org/101186/1472-6793-12-4.
30. Sax AT, Jenkins DG, Devin JL et al. The insulin-like growth factor axis: a biological mechanism linking physical activity to colorectal cancer survival. Cancer Epidemiol 2014; 38: 455-459.
31. Parrizas M, LeRoith D. Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology 1997; 138: 1355-1358.
32. Singh P, Alex JM, Bast F. Insulin receptor, and insulin-like growth factor receptor signalling systems novel treatment strategies of cancer. Med Oncol 2014; 31(805): https://doi.org/101007/s12032-013-0805-3.
33. Nowakowska-Zajdel E, Mazurek U, Wierzgoń J et al. Expression of ADAM 28 and IGFBP-3 genes in patients with colorectal cancer – a preliminary report. Int J Immunopathol Pharmacol 2013; 26: 223-228.
34. Liu JJ, Druta M, Shibata D et al. Metabolic syndrome and colorectal cancer: is hyperinsulineamia/insulin receptor-mediated angiogenesis a critical process? J Geriatr Oncol 2014; 5: 40-48.
35. Hakam A, Yeatman TJ, Lu L et al. Expression of insulin-like growth factor receptor in human colorectal cancer. Hum Pathol 1999; 30(10): 1128-1133.
36. Sandhu MS, Dunger DB, Giovanucci EL. Insulin, insulin-like growth factor-1, IGF bindings proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002; 94(13): 972-980.
37. Durai R, Yang W, Gupta S et al. The role of insulin-like growth factor system in colorectal cancer: a review of current knowledge. Int J Colorectal Dis 2005; 20: 203-220.
38. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16: 143-163.
39. Furlanetto RW, Harwell SE, Frick KK. Insulin-like growth factor-I induces cyclin-D1 expression in MG63 human osteosarcoma cells in vitro. Mol Endocrinol 1994; 8: 510-517.